Antibacterial drug company Trius Therapeutics Inc. brought in $30 million in its second venture round to advance into Phase II and Phase III studies with lead program, TR-701, an oxazolidinone antibiotic that has indicated promising results from an ongoing Phase I study. (BioWorld Today) Read More
